

Notice on Capital and Business Alliance Agreement with Aillis Inc., a Venture Company of AI Medical Equipment

OSAKA, Japan, May 10, 2019 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announces that it has entered into an agreement on capital and business alliance with Aillis Inc. (Head Office: Tokyo, Japan; President & CEO: Sho Okiyama; hereinafter, "Aillis") effective April 25, 2019.

Established in November 2017 with a mission slogan "Bringing Expertise to Every Medical Practice," Aillis is developing a medical equipment of high precision and early diagnosis using the AI (Artificial Intelligence) technology to provide support for diagnosis of influenza. Under the capital and business alliance, Shionogi has acquired about 14% of the shares in Aillis by investing 1.2 billion yen, and is entitled to a priority right for negotiation for a future license agreement concerning the AI medical equipment under development.

Shionogi's research and development efforts target infectious diseases as one of its priority areas, and Shionogi has positioned "protecting people from the threat of infectious diseases" as one of its core social missions. Through the alliance with Aillis, Shionogi strives constantly to contribute to early diagnosis and treatment of influenza.

For reference: Website of Aillis Inc. (Japanese only) : <https://aillis.jp/>

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885